公开(公告)号：US20210292418A1

公开(公告)日：2021-09-23

申请号：US17204604

申请日：2021-03-17

Applicant: GENMAB A/S

Inventor： Louise KOOPMAN ,  Patrick ENGELBERTS ,  Dennis VERZIJL ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Sieto BOSGRA ,  Frederikke L. EGEROD ,  David SATIJN ,  Esther C. W. BREIJ

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20180326084A1

公开(公告)日：2018-11-15

申请号：US15742818

申请日：2016-07-08

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Kirstine JACOBSEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Henrik Jørn DITZEL ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K47/6803 ,  A61K39/001102 ,  A61K45/06 ,  A61K47/6801 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2863 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.

公开(公告)号：US20190275149A1

公开(公告)日：2019-09-12

申请号：US16248402

申请日：2019-01-15

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K47/68

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20190022243A1

公开(公告)日：2019-01-24

申请号：US16069395

申请日：2017-01-13

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00

Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.

公开(公告)号：US20180214549A1

公开(公告)日：2018-08-02

申请号：US15938961

申请日：2018-03-28

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K47/6801 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61K2039/505 ,  A61K2121/00 ,  C07K16/2863 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20240317861A1

公开(公告)日：2024-09-26

申请号：US18539509

申请日：2023-12-14

Applicant: GENMAB A/S

Inventor： Isil ALTINTAS ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rik RADEMAKER ,  Paul PARREN ,  Bart DE GOEIJ

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/42

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/4258 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20210230296A1

公开(公告)日：2021-07-29

申请号：US17228023

申请日：2021-04-12

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20200277397A1

公开(公告)日：2020-09-03

申请号：US16813167

申请日：2020-03-09

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  C12N15/79 ,  A61P35/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240091352A1

公开(公告)日：2024-03-21

申请号：US18175894

申请日：2023-02-28

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K47/6801 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  C07K16/2863 ,  C07K16/3061 ,  A61K2039/505

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20230257479A1

公开(公告)日：2023-08-17

申请号：US17642488

申请日：2020-09-11

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C.W. BREIJ ,  Bart E.C.G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN ,  Reshma Abdulla RANGWALA ,  Sri GHATTA ,  Ruud BRAKENHOFF ,  Rieneke VAN DE VEN

IPC: C07K16/30 ,  A61P35/00 ,  A61P1/00

CPC classification number: C07K16/30 ,  A61P1/00 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).